Main |
Browse Volumes |
Forthcoming Volumes |
Annals PrePrints |
Annals Extra |
E-mail Alerts |
Subscriptions & Orders |
New Proposals |
Author Guidelines |
About Annals |
Help |
 |
|
|
|
|
|
Tularemia: History, Epidemiology, Pathogen Physiology, and Clinical Manifestations
ANDERS SJÖSTEDTa
a Department of Clinical Bacteriology, Clinical Microbiology, Umeå University, SE-901 85 Umeå, Sweden
Key Words: Francisella • tularemia • epidemiology • pathogen physiology • clinical manifestations
Address for correspondence: Anders Sjöstedt, Department of Clinical Bacteriology, Clinical Microbiology, Umeå University, SE-901 85 Umeå, Sweden. Voice: +46-90-785-1120; fax: +46-90-785-2225. anders.sjostedt{at}climi.umu.se
Francisella tularensis has been recognized as a human pathogen for almost 100 years and is the etiological agent of the zoonotic disease tularemia. Soon after its discovery, it became recognized as an important pathogen in several parts of the world, for example, in the United States and Soviet Union. The number of tularemia cases in the two countries peaked in the 1940s and has thereafter steadily declined. Despite this decline, there was still much interest in the pathogen in the 1950s and 1960s since it is highly infectious and transmissible by aerosol, rendering it a potent biothreat agent. In fact, it was one of the agents that was given the highest priority in the offensive programs of the United States and Soviet Union. After termination of the offensive programs in the 1960s, the interest in F. tularensis diminished significantly and little research was carried out for several decades. Outbreaks of tularemia during the last decade in Europe, for example, in Kosovo, Spain, and Scandinavia, led to a renewed public interest in the disease. This, together with a massive increase in the research funding, in particular in the United States since 2001, has resulted in a significant increase in the number of active Francisella researchers. This article summarizes, predominantly with a historical perspective, the epidemiology and clinical manifestations of tularemia and the physiology of F. tularensis.
This article has been cited by other articles:
|
|
|
|
 
J. F. Huntley, P. G. Conley, D. A. Rasko, K. E. Hagman, M. A. Apicella, and M. V. Norgard
Native Outer Membrane Proteins Protect Mice against Pulmonary Challenge with Virulent Type A Francisella tularensis
Infect. Immun.,
August 1, 2008;
76(8):
3664 - 3671.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. C. F. Oyston
Francisella tularensis: unravelling the secrets of an intracellular pathogen
J. Med. Microbiol.,
August 1, 2008;
57(8):
921 - 930.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. O'Toole, E. S. Williams, L. W. Woods, K. Mills, A. Boerger-Fields, D. L. Montgomery, P. Jaeger, W. H. Edwards, D. Christensen, and W. Marlatt
Tularemia in range sheep: an overlooked syndrome?
J Vet Diagn Invest,
July 1, 2008;
20(4):
508 - 513.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Qin, D. W. Scott, and B. J. Mann
Francisella tularensis subsp. tularensis Schu S4 Disulfide Bond Formation Protein B, but Not an RND-Type Efflux Pump, Is Required for Virulence
Infect. Immun.,
July 1, 2008;
76(7):
3086 - 3092.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Lembo, M. Pelletier, R. Iyer, M. Timko, J. C. Dudda, T. E. West, C. B. Wilson, A. M. Hajjar, and S. J. Skerrett
Administration of a Synthetic TLR4 Agonist Protects Mice from Pneumonic Tularemia
J. Immunol.,
June 1, 2008;
180(11):
7574 - 7581.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
